Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib

• Published in: Journal of clinical medicine 2021-12, Vol.11 (1), p.112
• Main Authors: Mikulski, Damian, Robak, Paweł, Perdas, Ewelina, Węgłowska, Edyta, Łosiewicz, Aleksandra, Dróżdż, Izabela, Jarych, Dariusz, Misiewicz, Małgorzata, Szemraj, Janusz, Fendler, Wojciech, Robak, Tadeusz
• Format: Article
• Language: English
• Subjects: Bone diseases; Chemotherapy; Clinical medicine; Cytokines; Drug dosages; Granulocytes; Hypercalcemia; Laboratories; Life sciences; Medical prognosis; Multiple myeloma; Patients; Proteins; Regression analysis; Stem cell transplantation; Survival analysis; Targeted cancer therapy; Tumor necrosis factor-TNF; Variables; Vascular endothelial growth factor
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm11010112

Multiple myeloma (MM) is characterized by the malignant proliferation of monoclonal plasma cells in the bone marrow with an elevation in monoclonal paraprotein, renal impairment, hypercalcemia, lytic bony lesions, and anemia. Immune cells and associated cytokines play a significant role in MM growth, progression, and dissemination. While some cytokines and their clinical significance are well described in MM biology, others remain relatively unknown. The present study examines the influence on progression-free survival (PFS) and overall survival (OS) by the serum levels of 27 selected cytokines in 61 newly diagnosed MM patients receiving first-line therapy with bortezomib-based regimens. The measurements were performed using a Bio-Rad Bio-Plex Pro Human Cytokine 27-Plex Assay and a MAGPIX Multiplex Reader, based on the Bio-Plex 200 System (Bio-Rad). The following levels were determined: IL-1β, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, Eotaxin, FGF, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF-BB, RANTES, TNF-α, and VEGF. Most patients received a VCD chemotherapy regimen (bortezomib, cyclophosphamide, and dexamethasone). In the final multivariate model, IL-13 cytokine level (HR 0.1411, 95% CI: 0.0240-0.8291, = 0.0302) and ASCT (HR 0.3722, 95% CI: 0.1826-0.7585, = 0.0065) significantly impacted PFS. Furthermore, ASCT (HR 0.142, 95% CI: 0.046-0.438, = 0.0007), presence of bone disease at diagnosis (HR 3.826, 95% CI: 1.471-9.949, = 0.0059), and two cytokine levels-IL-1Ra (HR 1.017, 95% CI: 1.004-1.030, = 0.0091) and IL-4 (HR 0.161, 95% CI: 0.037-0.698, = 0.0147)-were independent predictors of OS. Three clusters of MM patients were identified with different cytokine profiles. In conclusion, serum pretreatment levels of IL-13 and IL-4 are predictors of better PFS and OS, respectively, whereas IL-1Ra pretreatment levels negatively impact OS in MM patients treated with bortezomib-based chemotherapy. Cytokine signature profile may have a potential influence on the outcome of patients treated with bortezomib.